State of New Jersey Common Pension Fund D Acquires 1,847 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

State of New Jersey Common Pension Fund D grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,715 shares of the medical equipment provider’s stock after acquiring an additional 1,847 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Lantheus were worth $2,524,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Exchange Traded Concepts LLC bought a new position in Lantheus in the 3rd quarter worth about $68,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of Lantheus by 15.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 7,404 shares of the medical equipment provider’s stock valued at $514,000 after acquiring an additional 970 shares during the period. Shaker Investments LLC OH increased its holdings in Lantheus by 268.6% during the 3rd quarter. Shaker Investments LLC OH now owns 27,705 shares of the medical equipment provider’s stock worth $1,925,000 after acquiring an additional 20,189 shares during the period. Reinhart Partners LLC. lifted its stake in Lantheus by 25.9% in the 3rd quarter. Reinhart Partners LLC. now owns 901,520 shares of the medical equipment provider’s stock worth $62,638,000 after purchasing an additional 185,376 shares in the last quarter. Finally, Citizens National Bank Trust Department lifted its stake in Lantheus by 53.8% in the 3rd quarter. Citizens National Bank Trust Department now owns 12,530 shares of the medical equipment provider’s stock worth $871,000 after purchasing an additional 4,385 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

LNTH stock opened at $67.39 on Thursday. The firm has a market cap of $4.62 billion, a P/E ratio of 14.52 and a beta of 0.53. The firm’s fifty day moving average is $62.22 and its 200 day moving average is $62.69. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Research analysts predict that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. B. Riley increased their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Truist Financial reissued a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.71.

Insider Activity

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 94,545 shares of company stock valued at $6,169,936. 2.10% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.